Streetbeat News

Earnings

REGN

Regeneron Pharmaceuticals presented pivotal data on Linvoseltamab at AACR 2024, showing a high response rate in heavily pre-treated multiple myeloma patients. The study with 117 patients showed a 71% objective response rate, with significant percentages achieving complete responses or very good partial responses. The median duration of response, progression-free survival, and overall survival were not reached, indicating promising outcomes. Among patients with a complete response, 93% were minimum residual disease negative.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:37 am

LOT

MDIA

U.S. stocks closed higher on Friday, with the Dow Jones surging over 300 points, driven by positive jobs data and an improvement in investor sentiment as indicated by the CNN Money Fear and Greed index. The index remained in the 'Greed' zone. MediaCo Holding Inc. saw a significant jump in its shares after Standard General L.P. reported a 95.2% stake. Investors are also awaiting earnings results from Lotus Technology Inc.

Portfolio Pulse from Avi Kapoor

April 08, 2024 | 6:36 am

ITOS

iTeos Therapeutics is set to present preclinical data on EOS-984 at AACR 2024, showcasing its potential to restore T cell activity from adenosine suppression. This development could mark a significant advancement in cancer treatment strategies.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:26 am

MDT

Medtronic announced that its Evolut TAVR platform met both co-primary endpoints of clinical non-inferiority and hemodynamic superiority at one year in the largest head-to-head randomized control TAVR trial, demonstrating non-inferior clinical outcomes and superior valve performance compared to Sapien.

Portfolio Pulse from Charles Gross

April 07, 2024 | 2:11 pm

IONS

Ionis Pharmaceuticals announced that its drug olezarsen, in an 80 mg monthly dose, met the primary endpoint in a study by significantly reducing triglycerides in patients with FCS after six months. The results, which also showed a reduction in acute pancreatitis events, suggest olezarsen could be a novel treatment for this rare disease. The findings were presented at ACC 2024 and published in The New England Journal of Medicine. Ionis will host a webcast to discuss these results.

Portfolio Pulse from Charles Gross

April 07, 2024 | 2:08 pm

GOOG

GOOGL

TSLA

Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL) retains its title as America's Most Innovative Company for 2024 despite facing AI mishaps and internal criticism. CEO Sundar Pichai addresses the inaccuracies of the Gemini AI chatbot, amidst calls for his resignation. Apple and Microsoft are ranked second and third, respectively, in innovation. Alphabet's market capitalization stands at $1.906 trillion, with Bill Ackman expressing confidence in the company's investment potential despite AI challenges.

Portfolio Pulse from Ananya Gairola

April 07, 2024 | 12:21 pm

ADBE

AZN

BABA

DIA

GDX

SPY

The US manufacturing sector reached an 18-month high in March 2024, driven by strong performances in the SPDR Dow Jones Industrial Average ETF (DIA) and the SPDR S&P 500 (SPY). China's manufacturing growth could lead to global deflation, benefiting Alibaba Group Holding (BABA) and the VanEck Gold Miners ETF (GDX). The US labor market saw significant growth, with companies like AstraZeneca (AZN) and Adobe (ADBE) contributing. Critiques were made against the Federal Reserve's data-dependent strategy, and warnings were issued about a potential US debt crisis by 2025.

Portfolio Pulse from Benzinga Neuro

April 07, 2024 | 10:03 am

CANOO

KARS

NKLA

RIVN

TSLA

Electric vehicle stocks experienced a sell-off in the week ending April 5, influenced by broader market trends and company-specific news. Tesla reported its first year-over-year sales decline since Q2 2020, attributing it to production transitions and disruptions. Despite this, Ark Invest purchased $76 million in Tesla shares. Rivian celebrated its 100,000th vehicle production, while Nikola exceeded Q1 delivery expectations. Ford delayed its EV production plans, and Canoo's shares plummeted after a disappointing forecast. The KraneShares Electric Vehicles ETF saw a slight increase on Friday but fell overall for the week.

Portfolio Pulse from Shanthi Rexaline

April 06, 2024 | 1:17 pm

VTLE

Vital Energy (NYSE:VTLE) received mixed analyst ratings with 9 analysts providing their perspectives, showing a range of bullish to bearish sentiments. The average 12-month price target is $61.67, down 5.28% from the previous $65.11. Analyst actions include both upgrades and downgrades, with price targets adjusted accordingly. Vital Energy, an independent energy company, has shown strong financial performance with a revenue growth rate of 22.08%, a net margin of 63.21%, and an ROE of 12.33%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 9:00 pm

NRSN

NeuroSense Therapeutics (NASDAQ:NRSN) reported a Q4 EPS loss of $(0.16), surpassing the analyst consensus estimate of $(0.23) by 30.43%. This marks a 40.74% improvement over the $(0.27) per share loss from the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:49 pm